A randomized controlled study of tacrolimus for the treatment of idiopathic membranous nephropathy

ISRCTN ISRCTN17977921
DOI https://doi.org/10.1186/ISRCTN17977921
Secondary identifying numbers N/A
Submission date
11/05/2016
Registration date
28/05/2016
Last edited
18/10/2017
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Urological and Genital Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
Idiopathic membranous nephropathy (IMN) is a disease where the small blood vessels in the kidney become inflamed and thickened, causing proteins to leak into the urine. The aims of this study are to compare the effectiveness of a steroid combined with tacrolimus and tacrolimus alone for the treatment of IMN.

Who can participate?
Patients with IMN

What does the study involve?
Patients are randomly allocated into two groups: one group receives TAC alone, and the other group receives steroid combined with TAC. Patients are followed up for 6 months.

What are the possible benefits and risks of participating?
All patients will receive TAC for free, and will help us to provide a better treatment for IMN. The risks include adverse reactions to TAC, such as high blood pressure, angina pectoris, effusion and so on.

Where is the study run from?
The First Affiliated Hospital of Zhengzhou University (China)

When is the study starting and how long is it expected to run for?
June 2016 to June 2017

Who is funding the study?
The First Affiliated Hospital of Zhengzhou University (China)

Who is the main contact?
Zhanzheng Zhao
13938525666@139.com

Contact information

Mr Zhanzheng Zhao
Scientific

No.1 Jianshe Eastern Road
6th Floor of No.7th Building
Erqi District
Zhengzhou
450000
China

Phone +86 (0)139 38525666
Email 13938525666@139.com

Study information

Study designMulticenter randomized controlled clinical trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleA randomized controlled study of tacrolimus for the treatment of idiopathic membranous nephropathy
Study objectivesMembranous nephropathy (MN) is one of the most common pathological causes of nephrotic syndrome in adults. Idiopathic membranous nephropathy (IMN) accounts for approximately two-thirds of all MN cases. The clinical manifestations and prognosis vary greatly in IMN patients, and IMN may resolve without treatment, present as ongoing nephrotic syndrome, or progress to end-stage renal disease. No consensus on its treatment or widely accepted treatment protocol is currently available.

Tacrolimus (TAC), an immunosuppressant, is a substrate of cytochrome P450 3A (CYP3A) and P-glycoprotein (P-gp). Steroids are substrates and inducers of P-gp and CYP3A4 and potent inducers of multidrug resistance-associated protein 2 (MRP2) and UDP-glucuronosyltransferase (UGT). The plasma concentration of TAC increases after steroid withdrawal. In vivo pharmacokinetic studies in animals showed that TAC combined with prednisone decreases the plasma concentration of TAC and increases the elimination of TAC.

The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend the use of TAC for at least 6 months in patients who meet the criteria for initial treatment but are unwilling or contraindicated to receive cycles of steroids/alkylating agents (1C). TAC alone or in combination with a steroid is more effective for MN than conventional treatment regimens. However, no studies have been conducted to compare the efficacy and side effects of TAC alone and TAC combined with a steroid for the treatment of MN.

We hypothesize that in combination therapy of a steroid and TAC for IMN, the steroid will reduce the plasma concentration of TAC and make it necessary to increase the TAC dose, thereby increasing the side effects of TAC.
Ethics approval(s)The Ethics Committee of First Affiliated Hospital of Zhengzhou University, 25/12/2015, ref: Scientific 2015(35)
Health condition(s) or problem(s) studiedIdiopathic membranous nephropathy
Intervention1. Treatment regimen: The patients will be randomly assigned into one of the two groups: steroid + TAC group (P + T group) or TAC alone group (T group), and observed for 24 weeks.

Patients in the P + T group will be given prednisone 0.5 mg/kg/d (maximum dose: 30 mg/d); the dose will be tapered 2 weeks after the patient has achieved clinical remission, at a rate of 5 mg/d every 2 weeks; once the dose has been reduced to 10 mg/d, the dose will be tapered at a rate of 2.5 mg/d every two weeks until withdrawal; for patients who fail to achieve clinical remission within 4 weeks, the dose will be tapered as described above.

Patients in the T group will receive TAC 0.05 mg/kg/d (two doses per day, morning and night) 1 hour before or 2 hours after meals. The TAC dose is adjusted on the basis of its plasma concentration, and the goal is to maintain the plasma concentration in the range of 5–10 ng/mL. To reduce the TAC dose, for both groups, TAC will be reduced by 30% at 2 months after complete or partial clinical remission. The plasma concentration of TAC will be maintained at 3-6 ng/mL.

2. Concomitant medications: The following medications are prohibited: other immunosuppressants or cytotoxic drugs and anticoagulants.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Tacrolimus
Primary outcome measure1. Change in 24-hour urine protein from baseline and percent change
2. Change in serum albumin from baseline and percent change
Measured at baseline, 2, 4, 8, 12, 24 weeks.
Secondary outcome measures1. Changes in serum creatinine and eGFR from baseline and percent changes
2. Change in serum PLA2R antibodies from baseline
Measured at baseline, 2, 4, 8, 12, 24 weeks.
Overall study start date01/06/2016
Completion date30/06/2017

Eligibility

Participant type(s)Patient
Age groupAll
SexBoth
Target number of participants120
Key inclusion criteria1. Patients with idiopathic membranous nephropathy confirmed by renal biopsy (light microscopy + SEM)
2. Clinical manifestations of nephrotic syndrome
3. Persistent serum creatinine < 115 mmol/L or the reference value of creatinine
4. Any age group, male or female
Key exclusion criteria1. Secondary MN with hepatitis or malignant tumor
2. Use of steroids, cytotoxic drugs, or immunosuppressants within 3 months of this study
3. Other severe organ diseases
4. Fasting blood glucose > 6.2 mmol/L or confirmed diabetes
5. Pregnant or nursing women
Date of first enrolment01/06/2016
Date of final enrolment30/03/2017

Locations

Countries of recruitment

  • China

Study participating centres

The First Affiliated Hospital of Zhengzhou University
Zhengzhou
45000
China
The First Affiliated Hospital of Henan University of Chinese Medicine
Zhengzhou
450000
China
The First Affiliated Hospital of Henan University of Science and Technology
LuoYang
471023
China
LuoHe Central Hospital
LuoHe
671699
China
ZhuMaDian Central Hospital
ZhuMaDian
463699
China

Sponsor information

The First Affiliated Hospital of Zhengzhou University (China)
Hospital/treatment centre

No.1 Jianshe Eastern Road
6th Floor of No.7th Building
Erqi District
Zhengzhou
450000
China

Phone +86 (0)371 66295962
Email 13938525666@139.com
ROR logo "ROR" https://ror.org/056swr059

Funders

Funder type

Hospital/treatment centre

The First Affiliated Hospital of Zhengzhou University (China)

No information available

Results and Publications

Intention to publish date30/06/2018
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planTo be confirmed at a later date
IPD sharing plan

Editorial Notes

18/10/2017: Internal review.